Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
General11 hours agoFerries and celebrities as pollies dash to win the west
-
Noosa News16 hours agoCSIRO, winemakers pair to breed mildew, climate-resistant grapevines
-
Noosa News12 hours agoChild killer Rick Thorburn who murdered Tiahleigh Palmer found dead in jail cell
-
Noosa News19 hours agoSpinach salads back on supermarket shelves amid E. coli probe